跳至主要内容
临床试验/NCT02282761
NCT02282761已完成3 期

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Antipsychotic Efficacy of ITI-007 in Patients With Schizophrenia

Intra-Cellular Therapies, Inc.1 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2014年11月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
450
试验地点
1
主要终点
Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score

研究概览

简要总结

The study will be conducted as a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with schizophrenia having an acute exacerbation of psychosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • male or female subjects of any race, ages 18-60 inclusive, with a clinical diagnosis of schizophrenia
  • experiencing an acute exacerbation of psychosis

排除标准

  • any subject unable to provide informed consent
  • any female subject who is pregnant or breast-feeding
  • any subject judged to be medically inappropriate for study participation

研究组 & 干预措施

Lumateperone 28 mg (ITI-007 40 mg Tosylate)

Experimental

Lumateperone 28 mg (ITI-007 40 mg Tosylate) administered orally as formulated capsules once daily for 28 days

干预措施: ITI-007 (Drug)

Lumateperone 42 mg (ITI-007 60 mg Tosylate)

Experimental

Lumateperone 42 mg (ITI-007 60 mg Tosylate) administered orally as formulated capsules once daily for 28 days

干预措施: ITI-007 (Drug)

Placebo

Placebo Comparator

Placebo administered orally as formulated capsules once daily for 28 days

干预措施: Placebo (Drug)

结局指标

主要结局

Change From Baseline to Day 28 in Positive and Negative Syndrome Scale (PANSS) Total Score

时间窗: 28 days

The PANSS is a 30-item scale used to measure symptoms of schizophrenia. The scale has 7 positive symptom items, 7 negative symptom items, and 16 general psychopathology symptom items. Each item is scored on a 7-point scale by the clinical rater based on a clinical interview with the patient, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms. Thus, the PANSS Total score minimum is 30 and the maximum is 210, with higher numbers indicating more severe symptoms.

次要结局

  • Change From Baseline to Day 28 in Clinical Global Impressions-Severity of Illness Scale(28 days)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验